BiomX Inc.
PHGEBiomX Inc. is a biotechnology company focused on the development of microbiome-based therapies for various diseases. Utilizing its proprietary platform, it identifies and engineers beneficial bacteria to address conditions related to inflammation, metabolic disorders, and other chronic illnesses. The company aims to harness the microbiome's potential to offer novel, personalized treatment options.
Company News
BiomX announced that its subsidiary Zorronet has completed the transition to a new advanced data center designed to improve response times, cost efficiency, and capacity for handling complex security events in real time. The new infrastructure supports Zorronet's AI-powered command-and-control platform that integrates video analytics, drones, sen...
BiomX Inc. (PHGE) announced it has accelerated its option to acquire a controlling interest in DFSL, an Israeli defense engineering company specializing in LADAR-based detection systems for perimeter security and counter-UAS applications. The acquisition complements BiomX's recent Zorronet AI command-and-control platform acquisition, creating an ...
BiomX Inc. (NYSE: PHGE) has completed the acquisition of Zorronet from Water.io, an AI-powered command-and-control software platform that integrates video analytics, drones, sensors, and IoT devices for defense and security applications. The acquisition marks BiomX's entry into the defense sector and complements its option to acquire DFSL, a LADA...
BiomX Inc. (PHGE) announced it has entered into an option agreement to acquire control of DFSL, an Israeli developer of LADAR-based detection systems for security, defense, and critical infrastructure. DFSL's proprietary AI-integrated laser radar technology achieves approximately 99% accuracy in detecting UAVs and ground-based threats while signi...
BiomX Inc. announced a private placement financing of approximately $3.0 million gross proceeds through the issuance of Series Y Convertible Preferred Stock and warrants. The company plans to use net proceeds to assess opportunities for its bacteriophage programs, including BX011 for diabetic foot infections, and for general corporate purposes wh...
